InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,353.23
(
0.91%
)
Post# of 177
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1730
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: oc631 post# 128

Wednesday, 06/08/2011 10:15:52 AM

Wednesday, June 08, 2011 10:15:52 AM

Post# of 177
Counter point- Talking to myself again




If the strategy is to bring PSI-7977 monotherapy to market as a first generation oral compound there are clearly advantages to this line of thinking. By November PSI-7977 will have been through extensive phase 2 testing and it and will move much quicker through late stage testing than the dual nuke combination. That is if monotherapy is a viable option. The lack of interferon should also help expedite the process.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up